- Children aged 6 to 12 received a second dosage
- The trial is carried out by dividing the youngsters into age groups
- Children’s vaccination Covid-19 is also being tested by Zydus Cadila
With the arrival of new doses in the States and UTs, children aged 2-6 years will be given the second dosage of Bharat Biotech’s Covid-19 vaccine, Covaxin. The vaccine has already been administered to children aged 6 to 12 years from the next week.
Covaxin will be provided from the All India Institute of Medical Sciences (AIIMS) in New Delhi, which is one of the centers for vaccination studies for individuals under the age of 18.
In India, trials for a children’s Covid-19 vaccination are ongoing ahead of the predicted third wave of the Covid-19 pandemic. The head of AIIMS, Dr. Randeep Guleria had stated that the vaccination for children will most likely be ready in September.
The experiment is being carried out by categorizing children into age groups, with 175 youngsters from each age group participating. An intermediate report is due by the end of August, following the completion of the second dosage of vaccination. The interim report should reveal whether or not the vaccination is safe for youngsters.
Experts anticipate that Covaxin, also with Ahmedabad-based Zydus Cadila’s three-dose injection, ZyCov-D, would be approved for children in the coming days. While Covaxin is already being utilized in a countrywide immunization campaign, Zydus Cadila filed an emergency use authorization (EUA) application for their vaccine candidate for anyone aged 12 and above on July 1.
On the other hand, the Government has consistently said that additional data is needed before a children’s anti-coronavirus vaccination may be made accessible.